Introduction {#s1}
============

G protein-coupled receptors (GPCRs) are the most diverse class of integral membrane proteins with almost 800 members in humans. GPCRs are activated by a great diversity of extracellular stimuli including photons, neurotransmitters, ions, proteins, and hormones ([@bib20]). Upon activation, GPCRs couple to intracellular transducers, including four subtypes of G proteins (Gαs, Gαi/o, Gαq/11, Gα12/13) ([@bib44]), seven subtypes of GPCR kinases (GRKs) ([@bib24]), and four subtypes of arrestins ([@bib56]) ([Figure 1A](#fig1){ref-type="fig"}), among many other partners ([@bib41]). While most GPCRs are promiscuous and can couple to more than one G protein subtype ([@bib16]), the molecular determinants of G protein recognition are not yet fully understood. Understanding the molecular basis for G protein coupling and selectivity could lead to the design of drugs that promote specific signaling pathways and avoid unwanted side effects ([@bib25]).

![Cryo-EM structure of the rhodopsin-Gi-Fab16 complex.\
(**A**) GPCR signaling complexes. (**B**) EM density map of the complex (rhodopsin -- blue, Gαi -- green, Gβ -- yellow, Gγ -- magenta, Fab16 -- white). (**C**) Atomic model of the complex (same color code as B). The region of the Ras domain of Gα with no corresponding density in the EM map is depicted in back.](elife-46041-fig1){#fig1}

The recent surge in the number of structures of GPCR-G protein complexes has greatly expanded our understanding of G protein recognition and GPCR-mediated signal transduction. Out of the 13 structures of GPCR-G protein complexes available, six contain a Gi/o subtype: μ-opioid receptor bound to Gi ([@bib35]), adenosine A~1~ receptor bound to Gi ([@bib10]), cannabinoid receptor one bound to Gi ([@bib37]), human rhodopsin bound to Gi ([@bib31]), 5HT~1B~ receptor bound to Go ([@bib19]), and bovine rhodopsin bound to an engineered Go (mini-Go) ([@bib61]). However, the preparation of GPCR-G protein complexes for structural biology still remains challenging ([@bib45]). Nanobodies ([@bib51]), Fab fragments ([@bib31]; [@bib35]), and mini-G proteins ([@bib19]; [@bib61]) have been very important tools to overcome the inherent instability and flexibility of these complexes and obtain near atomic-resolution structures. Importantly, these structures represent snapshots of a particular state of the complex in the signaling cascade, and therefore additional structural data are required to improve our understanding of this process ([@bib5]).

The photoreceptor rhodopsin is one of the best-characterized model systems for studying GPCRs, providing invaluable information on how receptor activation is translated into G protein and arrestin binding and activation ([@bib28]; [@bib29]; [@bib55]). Rhodopsin has been shown to interact with the Gβγ subunit of the G protein heterotrimer to assist binding and activation of the Gα subunit ([@bib26]; [@bib27]). After dissociation of the Gαβγ heterotrimer, the Gβ subunit recruits GRKs to the membrane, resulting in the phosphorylation of the receptor C-terminal tail (C-tail) ([@bib8]; [@bib48]; [@bib50]) and binding of arrestin ([@bib22]). Despite this biochemical evidence, a direct interaction between rhodopsin and Gβγ could not be observed in the existing complex ([@bib31]).

Here, we present the cryo-EM structure of bovine rhodopsin in complex with a heterotrimeric Gi. Overall, our structure agrees well with current published structures ([@bib31]; [@bib61]). Remarkably, the EM density map provides structural evidence for the interaction between the C-tail of the receptor and the Gβ subunit. The density map also shows that intracellular loops (ICL) 2 and 3 of rhodopsin are at contact distance to Gα. This prompted us to perform a comparison of all available structures of GPCR-G protein complexes to generate a comprehensive contact map of this region. We then extended this analysis to the binding interface formed by the C-terminal helix α5 of Gα and found that only a few G protein subtype-specific residues consistently bind to the receptors. These contacts are ubiquitous anchoring points that may be also involved in the selective engagement and activation of G proteins.

Results {#s2}
=======

To obtain a rhodopsin-Gi complex suitable for structural studies, we expressed in HEK cells the constitutively active mutant of bovine rhodopsin N2C/M257Y/D282C ([@bib9]) which binds to the Gi protein heterotrimer ([@bib38]). The construct of the human Gαi1 subunit was expressed in *E. coli* ([@bib58]), while the Gβ1γ1 subunit was isolated from bovine retinae and thus contains native post-translational modification important for transducin function ([@bib43]). We reconstituted the rhodopsin-Gαi1β1γ1 complex in the detergent lauryl maltose neopentyl glycol (LMNG) ([@bib38]) in presence of Fab16 ([@bib39]) ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), as cryo-EM screening revealed that the complex without Fab could not be refined to high resolution ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}). During image processing ([Figure 1---figure supplements 3](#fig1s3){ref-type="fig"} and [4](#fig1s4){ref-type="fig"}), 3D classification revealed that the density corresponding to Gα is heterogeneous ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}), particularly at flexible regions such as the α-helical (AH) domain. The AH domain was then excluded by using a soft mask during refinement, resulting in a map with a nominal global resolution of 4.38 Å ([Figure 1---figure supplement 3D and E](#fig1s3){ref-type="fig"}). The EM map was used to build a model of the complex ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}).

Architecture of the rhodopsin-G protein complex {#s2-1}
-----------------------------------------------

The structure of rhodopsin-Gi-Fab16 reveals the features observed in previously reported GPCR-G protein complexes ([Figure 1B and C](#fig1){ref-type="fig"}; [Figure 1---figure supplement 7A](#fig1s7){ref-type="fig"}). In particular, our cryo-EM structure is in excellent agreement with the crystal structure of the same rhodopsin mutant bound to a mini-Go protein ([@bib61]), with a nearly identical orientation of the C-terminal α5 helix ([Figure 1---figure supplement 7B](#fig1s7){ref-type="fig"}), which contacts transmembrane helices (TM) 2, 3, 5--7 and the TM7/helix 8 (H8) turn of the receptor ([Figure 1---figure supplement 6B](#fig1s6){ref-type="fig"}).

Interaction between the C-terminal tail of rhodopsin and Gβ {#s2-2}
-----------------------------------------------------------

The EM map reveals a density on the Gβ subunit as continuation of H8 of the receptor ([Figure 2A](#fig2){ref-type="fig"}), which corresponds to the C-tail of rhodopsin. This feature has only been observed in the recent structure of the M1 muscarinic acetylcholine receptor in complex with G11 ([@bib40]). We modeled half of the C-tail of rhodopsin (12 out of 25 residues; 324--335) into this density as a continuous stretched peptide with residues G324, P327 and G329 serving as flexible hinges ([Figure 2B](#fig2){ref-type="fig"}). This allows us to compare the structure of this region in three conformational states of the receptor: inactive ([@bib46]), G protein-bound (this structure), and arrestin-bound ([@bib65]) ([Figure 2B](#fig2){ref-type="fig"}).

![The C-terminal tail of rhodopsin.\
(**A**) The EM map is contoured at two different levels to show the continuity of the density. The weakening at the end of H8 may arise from impaired interactions of the receptor with the detergent micelle ([@bib20]). TM7, H8 and the C-tail of the receptor are colored in blue, Gα in green, Gβ in yellow, and Gγ in magenta. (**B**) Conformational change of the C-tail between three different conformational states of rhodopsin: Inactive state (left, PDB id: 1U19), G protein-bound (center, this work), and arrestin-bound (right, PDB id: 5W0P, chain A). The Cα atoms of residues Asp330, Glu332 and Ser334 are shown as orange spheres to help tracking the structural changes in the C-tail. All structures are aligned to rhodopsin. (**C**) Schematic representation of the rhodopsin C-tail from Cys322 to Ala348. On the left, colored bars indicate the portion of the C-tail visible in this structure (green), and in the arrestin-bound structure (salmon) (PDB id: 5W0P). On the right, the residue-residue contacts between rhodopsin C-tail and Gα (marked in green), Gβ (yellow), and arrestin (salmon) within 4 Å distance are indicated. Thr336 and Ser338 are phosphorylated in the arrestin-bound structure. The predicted phosphorylation sites are marked with red dots. (**D**) Model of residue-residue interaction between the rhodopsin C-tail and the G protein subunits. Asn^H3.15^ and Lys^H3.16^ of the Gαi subunit forms the contact to the C-tail of rhodopsin near Glu332, Ala333 and Thr 335. In this model, the surface region of blades 6 and 7 of Gβ contact the C-tail via hydrophilic residues Cys271, Asp290, Asp 291, and Arg314.](elife-46041-fig2){#fig2}

In the inactive state, the C-tail folds around the cytoplasmic side of rhodopsin, although this is likely due to crystal packing as this region is intrinsically disordered in the absence of a binding partner ([@bib30]; [@bib62]).

In our G protein complex, the C-tail stretches over a polar surface on the cleft between Gα and Gβ, interacting with both subunits ([Figure 2C and D](#fig2){ref-type="fig"}). In Gβ, the interacting residues are C271, D290, and D291 in blade six and R314 in blade 7 of the β-propeller ([Figure 2D](#fig2){ref-type="fig"}), which impart a local negative electrostatic potential ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These residues are conserved in Gβ1--4 ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}) but not in Gβ5, the least similar to the other Gβ subtypes ([@bib13]). In Gα, the interacting residues with the C-tail are N256H3.15 and K257H3.16 in helix 3 of the Ras domain ([Figure 2D](#fig2){ref-type="fig"}), which confer instead a local positive electrostatic potential ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These residues are quite conserved across G protein subtypes except Gq ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Interestingly, these regions in Gα and Gβ that contact the receptor C-tail are also involved in recognition of GRK2 ([@bib59]).

In the rhodopsin-arrestin complex part of the proximal segment of the C-terminus (residues 325--329) is not resolved, but the distal part could be modeled up to S343, eight residues longer than in our G protein complex and including two phosphorylated sites. In the presence of arrestin, the C-tail stretches further, with residues K339-T342 forming a short β-strand antiparallel to the N-terminal β-strand of arrestin ([Figure 2B](#fig2){ref-type="fig"}).

Thus, it appears that distinct portions of the C-tail are responsible for contacting different intracellular partners. The central part of the C-tail (residues 330--335) can bind to Gα and Gβ, while the distal half of the C-tail (residues 336--343), which contains five (out of six) phosphorylation sites ([@bib2]), binds to arrestin ([Figure 2C](#fig2){ref-type="fig"}).

Comparison of the GPCR-G protein binding interface {#s2-3}
--------------------------------------------------

As in the other existing GPCR-G protein complex structures, the C-terminal α5 helix of Gα forms the major contact interface to rhodopsin. The α5 helix consists of the last 26 amino acids of Gα (H5.01--26), in which the last five residues fold into a hook-like structure ([@bib61]). The majority of the contacts formed by the α5 helix to GPCRs concentrate in the region from H5.11 to H5.26 ([@bib20]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

We aligned the structures of available complexes using the Cα atoms of H5.11--26. This alignment reduces apparent differences in the binding positions and provides the 'viewpoint of the G protein' ([Figure 3A](#fig3){ref-type="fig"}). We compiled an exhaustive list of the residue-residue contacts between the receptor and the α5 helix in all the available GPCR/G protein complexes, and observed that the main contacts to the α5 helix are formed by TM5 and TM6, followed by TM3 and TM7/8 ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

![Binding of the Gα α5 helix in GPCR-G protein complexes.\
(**A**) Overview of a subset of GPCR-G protein complexes used for this analysis. For a complete list of the complexes used, see [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}. The complexes are shown from the cytoplasmic side, and the black pentagons connecting TM2-3-5-6-7 delineate the G protein-binding interface. Receptors are represented in ribbons with their TM helices numbered. (**B**) The red surfaces depict the contact area (within a distance of 4 Å) between the receptor and the α5 helix of Gα (**C**) Schematic representation of the α5 helix in Gi- and Gs-subtypes. The residues highlighted, and their respective binding site to the receptor, are conserved among all Gi, and Gs, complexes analyzed. All contacts retrieved from this analysis are reported in [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}. (**D**) Position of Gi- and Gs-specific contacts shown in the rhodopsin-Gi (this work, PDB id: 6QNO) and the β~2~AR-Gs (PDB id: 3SN6) complexes. The cytoplasmic side of the receptors is depicted as gray surface. Red lines mark the border between TM5 and TM6 and delineate H8. (**E**) Cytoplasmic view of GPCR-G protein complexes showing the interaction between H5.17 (orange spheres) and TM5 and TM6. From left to right, the structures (PDB ids) correspond to: this work, 6G79, 6DDE, 6D9H, 3SN6, 6GDG, 5UZ7, and 5VAI. Throughout the analysis, contacts are defined as atomic distances smaller than 4 Å.](elife-46041-fig3){#fig3}

Gi/o-bound complexes have two conserved contacts: one between Gly^H5.24^ and the TM7/H8 turn, and one between Tyr/Phe^H5.26^ and TM6. In Gs-bound complexes, three distinct interactions are found: between Arg^H5.12^ and TM3/ICL2, and between Leu^H5.26^ and Arg^H5.17^ and TM5 ([Figure 3C,D](#fig3){ref-type="fig"}). In Gi/o complexes, the equivalent Lys^H5.17^ lies instead roughly parallel to TM6. Interestingly, Arg^H5.17^ appears to consistently interact with residue 5.68 in class A GPCRs, and with Lys^5.64^ in class B GPCRs ([Figure 3E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). We suggest that a tight interaction between Arg^H5.17^ and TM5 might be one of the main determinants for the Gs-specific relocation of TM6.

Besides the canonical interaction with the α5 helix, our complex shows that ICL2 and ICL3 of the receptor are at contact distance to Gi ([Figure 3---figure supplement 3A](#fig3s3){ref-type="fig"}). In all analyzed structures, we found that ICL2 lies near αN/β1 and β2/β3 of Gα, while ICL3 is close to α4/β6 ([Figure 3---figure supplements 3](#fig3s3){ref-type="fig"} and [4](#fig3s4){ref-type="fig"}). Interestingly, ICL2 folds into an α-helical structure in all the class A receptors except rhodopsin ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}).

ICL2 does not contribute to binding Gα in the structures of 5HT~1B~-mini-Go and A~1A~R-Gi. Nevertheless, the contact between Gα and ICL2 seems to discriminate between class A GPCRs --which interact via the αN/β1 loop-- and class B GPCRs --which instead the region around β1 and β2/β3 ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}).

ICL3, one of the most diverse regions in GPCRs, is often not completely resolved in the available structures ([Figure 3---figure supplement 3D](#fig3s3){ref-type="fig"}), either because it is too flexible or because it has been engineered to facilitate structural determination ([@bib45]). Gi/o-coupled receptors use residues on TM5/ICL3/TM6 to contact the α4/β6 region, while Gs-coupled receptors mainly use TM5/ICL3 ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). This difference is due to the larger displacement of TM6 in Gs complexes. In ICL3, residue Tyr^G.S6.02^, highly conserved in all G protein subtypes, engages the receptor in about half of all the complexes. This residue has been shown to be crucial for the stabilization of the rhodopsin-Gi complex ([@bib58]).

Thus, our analysis suggests that ICL2 and ICL3 contribute to the binding interface between receptor and G protein, a feature that may be required to further stabilize the complex during nucleotide exchange.

Discussion {#s3}
==========

In this work, we present the cryo-EM structure of the signaling complex between bovine rhodopsin and a Gi protein heterotrimer, stabilized using an antibody Fab fragment (Fab16) ([@bib39]). Overall, this structure agrees very well with existing complexes. In particular, we found that the binding mode of the G protein Ras domain --including the key C-terminal α5 helix-- is virtually identical to our previously reported X-ray structure of the same receptor bound to a mini-Go protein ([@bib61]) ([Figure 1---figure supplement 7B](#fig1s7){ref-type="fig"}).

However, our EM map shows a density on the Gβ subunit that extends from H8 of the receptor, constituting the proximal segment of the C-terminus (residues G324 to T335) ([Figure 2](#fig2){ref-type="fig"}). One explanation of why the C-tail is observed in our density map and not in other structures may rely on the nature of the components used to reconstitute the reported GPCR complexes ([Figure 1---figure supplement 8](#fig1s8){ref-type="fig"}). Among those, a meaningful comparison may be done with the μ-opioid receptor complex ([@bib35]), which is bound to a shorter version of our antibody Fab16, but in which the C-terminus of the receptor was partially truncated. In the human rhodopsin complex ([@bib31]), which contains the full length C-tail, a recombinant Gβγ was used. Thus, our bovine rhodopsin complex contains the unique combination of a full-length C-tail, Gβγ purified from bovine rod outer segments, and Fab16 that may have contributed to trap the transient interaction of the intrinsically disordered C-tail to Gβ. Remarkably, the recently published structure of the M1 muscarinic acetylcholine receptor in complex with G11 and scFv16 ([@bib40]) reveals part of the receptor C-tail bound to the G protein in essentially the same conformation as in our structure ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).

The Gβγ subunit engages with a wide range of effectors ([@bib13]; [@bib33]), including direct interactions with GPCRs. For instance, these can associate prior to trafficking to the plasma membrane ([@bib12]) where they can remain pre-coupled ([@bib17]). Also, according to a sequential fit model ([@bib26]; [@bib27]), activated rhodopsin binds to Gβγ assisting to position the Ras domain of Gα into proximity of its binding site to the receptor. This would facilitate folding of the C-terminal α5 helix of this subunit leading to nucleotide exchange ([@bib11]; [@bib15]; [@bib32]). After dissociation of the G protein heterotrimer, the Gβ subunit recruits GRKs to the membrane, resulting in the phosphorylation of the receptor C-tail ([@bib8]; [@bib48]; [@bib50]) and binding of arrestin ([@bib22]). Interestingly, HEK cells lacking functional Gα subunits (but retaining the native Gβγ) are still able to recruit arrestin, although they fail to activate ERK and whole-cell responses ([@bib23]).

Our findings provide a structural explanation for these roles of Gβγ in GPCR-mediated signaling. We suggest that the observed interaction between the central part of the receptor C-terminus and Gβγ is involved in localizing the G protein heterotrimer to the active receptor first. After dissociation of the Gα subunit, a transient Gβγ/receptor complex could provide the adequate molecular context to allow receptor phosphorylation by bringing the kinase close to the receptor C-tail ([@bib52]).

In other class A GPCRs, interactions with Gβγ have been also located in ICL3 (in M2 and M3) muscarinic receptors, involved in the phosphorylation of this loop ([@bib63]) and potentially in ICL1 (in A~2~AR and β~2~AR) ([@bib18]). In our complex, K6612.48 and K6712.49 in ICL1 are indeed close to D312 in Gβ (7 Å between Cα atoms); however, we do not observe defined density for the side chains in this region ([Figure 1---figure supplement 6A](#fig1s6){ref-type="fig"}). Interestingly, the complexes of the class B GPCRs calcitonin and GLP-1 feature an extended and tilted H8 resulting in extensive contacts with Gβγ that have not been observed in Class A receptors ([@bib18]). H8 has also been shown to bind Gβγ in the class B PTH1 receptor ([@bib42]). Thus, it is likely that class A and class B GPCRs use distinct mechanisms to engage Gβγ.

The receptor-Gβγ interaction observed in our structure is compatible with proposed models of receptor-GRK recognition ([@bib36]; [@bib54]). Thus, we suggest that the Gβγ subunit can 'tag' activated GPCRs and provide an interface for bringing different effectors (Gα subunits first, and GRKs later) near the cytoplasmic domains of GPCRs.

The availability of several GPCR-G protein complexes has greatly advanced our understanding on how receptors activate the Gα subunit ([@bib11]; [@bib15]). The binding interface of the receptor is partially formed by ICL2 and ICL3 ([@bib7]; [@bib20]; [@bib58]). Accordingly, our EM map shows that these domains are in close proximity to G ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). In particular, we found that ICL2 is at contact distance to the αN helix, the αN/β1 and the β2/β3 Gα in most structures ([Figure 3---figure supplements 3](#fig3s3){ref-type="fig"}--[5](#fig3s5){ref-type="fig"}). While ICL2 contributes to the binding interface, there are no apparent conserved contacts among complexes ([Figure 3---figure supplement 4](#fig3s4){ref-type="fig"}). However, at the interface between receptor and the α5 helix of the G protein, in all Gi complexes Phe^H5.26^ and Gly^H5.24^ contact TM6 and TM7/H8 of the receptor, respectively. Instead, in all Gs complexes we find that Leu^H5.26^, Arg^H5.17^ and Arg^H5.12^ contact TM5/ICL3, TM5, and TM3/ICL2, respectively. In a recent analysis ([@bib20]), it was proposed that residues 5.68 (class A GPCRs) and 5.64 (class B GPCRs) are particularly important for Gs protein binding. We observe that residue 5.68 interacts with H5.16 in both Gi- and Gs-bound complexes, but only with Arg^H5.17^ in all Gs complexes ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). While our analysis is limited by the number of available structures, we suggest that the conserved contacts identified between α5 and the receptors are structurally important anchoring points, but we cannot exclude that they might be relevant at the level of recognition between G protein subtypes.

In order to visualize snapshots of the signaling pathway that have not been observed yet, more work on the structural characterization of complexes is still needed, ideally using the same receptor and different transducers. Such complexes are of pivotal importance to decipher the structural basis of the GPCR-mediated signaling cascade.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                           Designation                                                                     Source\                                Identifier                                               Addition\
  (species) or resource                                                                                                   or reference                                                                                    information
  --------------------------------------- ------------------------------------------------------------------------------- -------------------------------------- -------------------------------------------------------- ------------------------------------------------------------------
  Strain, strain background (*E. coli*)   BL21(DE3)                                                                       Sigma-Aldrich                          SA: CMC0014                                              

  Cell line (*H. sapiens*)                HEK293 GnTI^-^                                                                  Reeves laboratory (gift)               Under MTA with MIT, Cambridge, MA, US.                   PMID: [12370423](https://www.ncbi.nlm.nih.gov/pubmed/12370423)

  Cell line (*M. musculus)*               Hybridoma                                                                       Hoffmann-La Roche (by collaboration)   Under MTA with Hoffmann-La Roche, Basel, Switzerland.    [@bib39]

  Biological sample (*B. taurus*)         Bovine retinae                                                                  WL Lawson Company (USA)                                                                         <https://wllawsoncompany.com/>

  Chemical compound, drug                 Blue Sepharose 6 Fast Flow                                                      GE Healthcare                          GEH: 17094801                                            

  Chemical compound, drug                 Chelating Sepharose Fast Flow immobilized metal affinity chromatography resin   GE Healthcare                          GEH: 17057501                                            

  Chemical compound, drug                 HiTrap Protein G Sepharose HP column                                            GE Healthcare                          GEH: 17040401                                            

  Chemical compound, drug                 Immobilized papain agarose resin                                                Thermo Scientific                      TS: 20341                                                

  Chemical compound, drug                 Protein A Sepharose                                                             GE Healthcare                          GEH: 17078001                                            

  Chemical compound, drug                 CNBr-activated sepharose 4B                                                     GE Healthcare                          GEH: 17043001                                            

  Chemical compound, drug                 Ultra-low IgG fetal bovine serum                                                Gibco                                  Gibco: 16250078                                          

  Chemical compound, drug                 Interleukin-6 recombinant mouse protein                                         Invitrogen                             Invitrogen: PMC0064                                      

  Chemical compound, drug                 cOmplete EDTA-free protease inhibitor cocktail                                  Sigma-Aldrich                          SA: 1873580001                                           

  Chemical compound, drug                 Dodecyl β-maltoside                                                             Anatrace                               Anatrace: D310                                           

  Chemical compound, drug                 Lauryl-maltoside neopentyl glycol                                               Anatrace                               Anatrace: NG310                                          

  Chemical compound, reagent              1D4 antibody                                                                    Cell Essentials Inc                                                                             <http://www.cell-essentials.com/>

  Chemical compound, drug                 1D4 peptide                                                                     Peptide 2.0                                                                                     <https://www.peptide2.com/>

  Chemical compound, drug                 9-cis retinal                                                                   Sigma-Aldrich                          SA: R5754                                                

  Chemical compound, drug                 Apyrase                                                                         New England Biolabs                    NEB: M0398                                               

  Software, algorithm                     XDS                                                                                                                    <http://xds.mpimf-heidelberg.mpg.de>                     PMID: [20124692](https://www.ncbi.nlm.nih.gov/pubmed/20124692);\
                                                                                                                                                                                                                          RRID: [SCR_015652](https://scicrunch.org/resolver/SCR_015652)

  Software, algorithm                     PHENIX                                                                                                                 <https://www.phenix-online.org>                          [@bib1];\
                                                                                                                                                                                                                          RRID: [SCR_014224](https://scicrunch.org/resolver/SCR_014224)

  Software, algorithm                     UCSF Chimera                                                                                                           <https://www.cgl.ucsf.edu/chimera>                       [@bib49];\
                                                                                                                                                                                                                          RRID: [SCR_004097](https://scicrunch.org/resolver/SCR_004097)

  Software, algorithm                     PyMOL                                                                           Schrödinger LLC                        <https://pymol.org>                                      RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)

  Software, algorithm                     FOCUS                                                                                                                  <https://focus.c-cina.unibas.ch/about.php>               [@bib4]

  Software, algorithm                     MotionCor2                                                                                                             <http://msg.ucsf.edu/em/software/motioncor2.html>        [@bib64];\
                                                                                                                                                                                                                          RRID: [SCR_016499](https://scicrunch.org/resolver/SCR_016499)

  Software, algorithm                     cryoSPARC                                                                       Structura Biotechnology Inc.           <https://cryosparc.com>                                  PMID: [28165473](https://www.ncbi.nlm.nih.gov/pubmed/28165473);\
                                                                                                                                                                                                                          RRID: [SCR_016501](https://scicrunch.org/resolver/SCR_016501)

  Software, algorithm                     RELION 2, 3                                                                                                            <http://www2.mrc-lmb.cam.ac.uk/relion>                   RRID:[SCR_016274](https://scicrunch.org/resolver/SCR_016274)

  Software, algorithm                     NAMD                                                                                                                   <http://www.ks.uiuc.edu/Research/namd>                   RRID:[SCR_014894](https://scicrunch.org/resolver/SCR_014894)

  Software, algorithm                     Coot                                                                                                                   <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot>   [@bib14];\
                                                                                                                                                                                                                          RRID: [SCR_014222](https://scicrunch.org/resolver/SCR_014222)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression and purification {#s4-1}
-----------------------------------

The N2C/M257Y/D282C mutant of bovine rhodopsin was expressed as described ([@bib9]) in human embryonic kidney (HEK) 293 GnTI-deficient cells (gift from Philip Reeves), which retain all post-translational modifications of the native protein including palmitoylation of Cys residues at positions 322 and 323 ([@bib57]). Cell lines were tested and confirmed to be mycoplasma-free. The human Gαi subunit (Gαi1) with an N-terminal TEV protease-cleavable deca-histidine tag was expressed in the *E. coli* BL21 (DE3) strain (Sigma: CMC0014) and purified as described ([@bib58]). The transducin heterotrimer was isolated from the rod outer segment of bovine retina (W L Lawson Company) and Gβ1γ1 was separated from Gαt with Blue Sepharose 6 Fast Flow (GE Healthcare) as described ([@bib38]). The Gαi1β1γ1 heterotrimer (Gi) was prepared by mixing equimolar amounts of Gαi1 with or without 10xHis-tag and Gβ1γ1 and incubated at 4°C for 1 hr shortly before use for rhodopsin-Gi complex formation on the 1D4 immunoaffinity column.

Fab16 production {#s4-2}
----------------

The monoclonal mouse antibody IgG16 was generated as described ([@bib35]). Large scale production of IgG16 was performed using adherent hybridoma cell culture (Hoffmann-La Roche, collaboration) grown in DMEM medium supplemented with 10% ultra-low IgG fetal bovine serum (FBS) (Gibco, \#16250078) and 25 U/ml of mouse interleukin-6 (Invitrogen, \#PMC0064) at 37°C and 5% CO~2~. Antibody expression was increased by stepwise dilution of FBS concentration down to 2%. After incubation for 10--14 days,\~500 ml cell suspension containing the secreted IgG was clarified by centrifugation and subsequent filtration through a 0.45 µm HAWP membrane (Merck Millipore). The filtrate was mixed with an equal volume of binding buffer (20 mM Na~2~HPO~4~/NaH~2~PO~4~, pH 7.0) and loaded to a 1 ml HiTrap Protein G Sepharose FF column (GE Healthcare). The column was washed with binding buffer until the UV~280~ absorbance dropped to a stable baseline, and IgG was eluted with 0.1 M glycine-HCl (pH 2.7). Fractions were immediately neutralized with 1 M Tris-HCl (pH 9.6). Fractions containing IgG16 were combined and dialyzed against 20 mM Na~2~HPO~4~/NaH~2~PO~4~ (pH 7.0), 1.5 mM NaN~3~ using a slide-A-lyzer dialysis cassette (12--14 kDa MWCO, Thermo Scientific) at 4°C for 15 hr. The dialysate was collected and mixed with the immobilized papain resin (0.05 ml resin for 1 mg IgG) (Thermo Scientific, \#20341). Papain was activated by the addition of L-cysteine and EDTA to a final concentration of 20 mM and 10 mM respectively. IgG was digested overnight at 37°C with gentle mixing. Afterwards the immobilized papain resin was removed and the digested fraction was mixed with Protein A Sepharose (0.2 ml resin for 1 mg digested IgG, GE Healthcare, \#17078001) for 1 hr at RT. Resins were washed with two column volumes (CV) of wash buffer 10 mM Tris (pH 7.5), 2.5 M NaCl. The flow-through and washing fractions containing Fab16 were collected and dialyzed against PBS supplemented with 1.5 mM NaN~3~ using a slide-A-lyzer dialysis cassette (12--14 kDa MWCO) at 4°C. The dialysate was collected and concentrated with a VivaSpin 20 concentrator (10 kDa MWCO, Sartorius) to approximately 1.1 mg/ml. Glycerol was supplemented to the concentrated Fab16 at a final concentration of 10%, and protein was flash frozen in liquid nitrogen and stored at −20°C until use for formation of the rhodopsin-Gi-Fab16 complex.

Fab16 crystallization and structure determination {#s4-3}
-------------------------------------------------

For its crystallization, Fab16 was further purified by SEC on a Superdex 200 Increase 10/300 GL column (GE Healthcare) equilibrated in buffer 10 mM Tris (pH 7.5), 50 mM NaCl. Fractions containing pure Fab16 were collected and concentrated to approximately 14 mg/ml using a VivaSpin four concentrator (10 kDa MWCO, Sartorius). Fab16 was crystallized by vapor diffusion at 4°C by dispensing 200 nl of protein and 200 nl of crystallization buffer containing 1.5 M malic acid (pH 7.5), 7% (v/v) LDAO in an MRC 2-well crystallization plate (Swissci) using a mosquito crystallization robot. Crystals appeared after one day and grew to full size within 4 days. Crystals were soaked in the reservoir solution supplemented with 20% (v/v) PEG 400 as a cryo-protectant and flash frozen in liquid nitrogen. The X-ray data was collected at the PXI beam line at the Swiss Light Source (SLS). Bragg peaks were integrated using XDS for individual datasets. XSCALE was used to scale and combine six datasets, and the pooled reflection list was further analyzed using the STARANISO server (Global Phasing Ltd.). The STARANISO server first analyzed the anisotropy for each dataset, giving a resolution of 1.90 Å in overall, 1.90 Å in the *0.92 a\* - 0.38 c\** direction, 2.25 Å in the *k* direction, and 2.13 Å in the *−0.14 a\* + 0.99 c\** direction under the criterion of CC½=0.3., following by scaling and merging of the reflections. The light chain from PDB id: 1MJU and the heavy chain from PDB id 2AAB without the CDR regions were used for molecular replacement using the program *Phaser-MR* in the Phenix suite. The model was built automatically using the Phenix *AutoBuild*, and the coordinates were manually adjusted using the visualization program Coot. The structure was refined using the *phenix.refine* to 1.90 Å ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The structure factor and the coordinates are deposited to the Protein Data Bank under the accession code 6QNK.

Purification of the rhodopsin-Gi-Fab16 and the rhodopsin-Gi complexes {#s4-4}
---------------------------------------------------------------------

Buffers for every purification step were cooled to 4°C before use, and the steps after adding retinal were performed under dim red light before light activation of rhodopsin. The stabilized, constitutively active rhodopsin mutant N2C/M257Y/D282C was expressed in HEK293 GnTI^-^ deficient cells as described ([@bib9]). The cells were collected from the cell culture by centrifugation and homogenized in PBS buffer with cOmplete EDTA-free protease inhibitor (Roche). The cells were solubilized by supplementing dodecyl maltoside (DDM) (Anatrace, Sol-grade) to final concentrations of cell at 20% (w/v) and of DDM at 1.25% (w/v). After gentle stirring for 1--2 hr, the solubilized fraction was collected after centrifugation at 200,000x g for 1 hr. Solubilized rhodopsin apoprotein was captured in batch using the immunoaffinity Sepharose beads (GE Healthcare, \#1043001) coupled to 1D4 antibody for more than 4 hr at the ratio of 5 g cells per ml resin. 1D4 resins were collected and washed with 10 CV of PBS, 0.04% DDM. Afterwards, resins were resuspended in 2 CV of PBS, 0.04% DDM and 75 µM of 9-cis (Sigma) or 11-cis retinal (Roche, or from NIH) for at least 6 hr in the dark. Later resins were washed with 30 CV of buffer A containing 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM MgCl~2~, 0.02% (w/v) lauryl-maltose neopentyl glycol (LMNG) to wash off unbound retinal. Washed resins were resuspended in 1 CV of buffer A and mixed with 10xHis-tagged Gi heterotrimer at the ratio of 2 mg Gi per ml resin with the presence of 25 mU/ml apyrase (New England Biolabs). The resuspended resin/Gi mixture was subjected to irradiation for 10--15 min with light that had been filtered through a 495 nm long-pass filter to induce activation of rhodopsin and G protein binding, followed by a 30 min incubation in the dark to allow full hydrolysis of nucleotide by apyrase. Resins were washed with 8 CV of buffer A to remove unbounded Gi heterotrimer. rhodopsin-Gi complex was eluted three times in batch with 1.5 CV of buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM MgCl~2~, 0.02% LMNG, 80 µM 1D4 peptide (TETSQVAPA) for at least 2 hr incubation each time. Elution fractions were combined and incubated for at least 2 hr with Ni-NTA resins (0.5--2 ml), washed with 6 CV of 20 mM HEPES (pH 7.5), 150 mM NaCl, 50 mM imidazole, 0.01% LMNG to remove free rhodopsin. Rhodopsin-Gi was eluted five times with 1 CV of 20 mM HEPES (pH 7.5), 150 mM NaCl, 350 mM imidazole, 0.01% LMNG. Elution fractions were immediately concentrated using an Amicon Ultra concentrator (MWCO 100 kDa) with simultaneous buffer exchange to 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.01% LMNG. Rhodopsin-Gi was mixed with molar excess (1:1.4) of Fab16 and incubated for at least 1 hr. The mixture of rhodopsin-Gi and Fab16 was concentrated using an Amicon Ultra concentrator (MWCO 30 kDa) and loaded to a Superdex 200 Increase 10/300 GL column for SEC with detergent-free buffer containing 20 mM HEPES (pH 7.5), 150 mM NaCl. Protein quality of each fraction was evaluated by UV-VIS measurement and SDS-PAGE. Fractions showing OD~280~/OD~380~ = \~5.9 (ratio between 280 and 380 nm) was chosen for cryo-EM studies. For preparation of rhodopsin-Gi complex, purified rhodopsin and 10xHis-tag-free Gi heterotrimer were mixed in a test tube in equimolar ratio with the presence of 25 mU/ml of apyrase and incubated for 1 hr at 4°C. The protein mixture was concentrated and purified using a Superdex 200 Increase 10/300 GL column. Fractions showing OD~280~/OD~380~ = 3 were used to prepare cryo-EM specimens.

Cryo-electron microscopy and image analysis {#s4-5}
-------------------------------------------

Purified samples of rhodopsin-Gi with and without Fab16 were plunge-frozen in a Vitrobot MarkIV (FEI Company) operated at 4°C and 90% humidity. A drop of 3.5 µL sample at 0.2 mg/mL was dispensed onto a glow discharged lacey carbon grid (Ted Pella, Inc) and blotted for 2--3 s before vitrification in liquid ethane. Images were acquired by a Titan Krios microscope operated at 300 kV equipped with a Falcon III, or with a K2 Summit and GIF energy filter ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Datasets were pre-processed and pruned in FOCUS ([@bib4]) using MotionCor2 ([@bib64]) with dose weighting for movie alignment, and CTFFIND4 ([@bib53]) for micrograph contrast transfer function estimation. Automated particle picking was performed in Gautomatch (<http://www.mrc-lmb.cam.ac.uk/kzhang/Gautomatch/>) and all further processing steps were carried in cryoSPARC (Structura Biotechnology Inc) and RELION 2 and 3 ([@bib34]; [@bib66]). Around 115,000 particles from the three best resolved 3D classes were pooled and subjected to 3D auto-refinement with a soft mask which deliberately excludes the density of the AH domain observed in one of the 3D classes. Map sharpening and modulation transfer function (MTF) correction were performed with RELION post-processing. The resulting map has a nominal resolution of 4.38 Å estimated following the gold standard Fourier Shell Correlation (FSC) at FSC = 0.143. Local resolution estimation was performed using *blocres* ([@bib6]).

Model building and structure refinement {#s4-6}
---------------------------------------

The initial models of rhodopsin and the Ras-like domain of Gαi protein were adapted from the structure of rhodopsin-mini-Go complex (PDB id: 6FUF). The initial model of Gβγ was obtained from the crystal structure of guanosine 5'-diphosphate-bound transducin (PDB id: 1GOT). The models were docked into the 3D map as rigid bodies in Chimera ([@bib49]). After initial refinement using the phenix.real_space_refine in the Phenix suite ([@bib1]), the C-tail of rhodopsin was modeled by manually building the residues 324--335 in the unassigned density near H8 and Gβ as a continuation of H8 using Coot ([@bib14]). The coordinates of the entire structure were improved by further refinement using phenix.real_space_refine and manual adjustment in Coot iteratively. This final placement of the C-tail was then validated by using the molecular dynamics flexible fitting (MDFF) method ([@bib60]). This technique allows to use electron density data as an external potential added to the molecular mechanics force field, thus taking advantage of the features present in the density while retaining a chemically sound structure. We observed that the modeled C-tail remains stable during the simulation ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}), supporting a good agreement between the built atomic structure and the density map.

Structure and sequence analysis {#s4-7}
-------------------------------

Structural models were downloaded from the Protein Data Bank. For comparing structures of the GPCR-G protein complexes, the residue-residue contacts within 4 Å were first identified using PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC). Electrostatic potentials were calculated using the APBS method ([@bib3]) as implemented in PyMOL using a concentration of 0.150 M for the +1 and −1 ion species. The biomolecular surface is colored from red (−5 kT/e) to blue (+5 kT/e) according to the potential on the soluble accessible surface. A sequence alignment of mammalian Gα proteins was obtained from the GPCRdb ([@bib47]). The MDFF simulation (1ns) was performed using Namdinator ([@bib60]) with default parameters (temperature: 298 K; G-force scaling factor: 0.3; Phenix RSR cycles: 5).

Figure preparation {#s4-8}
------------------

Figures were prepared using ChimeraX ([@bib21]) and PyMOL (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC).

Data availability {#s4-9}
-----------------

The cryo-EM density map is deposited under accession code EMD-4598 on the EM Data Bank. The related structure coordinates of the rhodopsin-complex bound to Fab16 (accession code 6QNO) and the crystal structure of Fab16 (accession code 6QNK) are deposited on the Protein Data Bank.
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Data availability {#s7}
=================

The cryo-EM density map of the rhodopsin-Gi complex bound to Fab16 has been deposited in the EM Data Bank (accession code EMD-4598), and the related structure coordinates have been deposited in the Protein Data Bank (accession code 6QNO). The crystal structure of Fab16 has been deposited in the Protein Data Bank (accession code 6QNK). Source data for Figure 3 is provided in Suppl. Table 3.

The following datasets were generated:

TsaiCJMarinoJAdaixoRJPamulaFMuehleJMaedaSFlockTTaylorNMIMohammedIMatileHDawsonRJPDeupiXStahlbergHSchertlerGFX2019Rhodopsin-Gi protein complexElectron Microscopy Data BankEMD-4598

TsaiCJMarinoJAdaixoRJPamulaFMuehleJMaedaSFlockTTaylorNMIMohammedIMatileHDawsonRJPDeupiXStahlbergHSchertlerGFX2019Rhodopsin-Gi protein complexProtein Data Bank6QNO

TsaiCJMuehleJPamulaFDawsonRJPMaedaSDeupiXSchertlerGFX2019Antibody FAB fragment targeting Gi protein heterotrimerProtein Data Bank6QNK

The following previously published datasets were used:

TsaiCJWeinertTMuehleJPamulaFNehmeRFlockTNoglyPEdwardsPCCarpenterBGruhlTMaPDeupiXStandfussJTateCGSchertlerGFX2018Crystal structure of the rhodopsin-mini-Go complexProtein Data Bank6FUF

LambrightDGSondekJBohmASkibaNPHammHESiglerPB1997Heterotrimeric complex of a Gt-alpha/Gi-alpha chimera and the Gt-beta-gamma subunitsProtein Data Bank1GOT

ChangCCHernandez-GuzmanFGLuoWWangXFerroneSGhoshD2005Structural basis of antigen mimicry in a clinically relevant melanoma antigen systemProtein Data Bank2AAB

ZhuYWilsonIA2002Crystal structure of murine class II MHC I-Ab in complex with a human CLIP peptideProtein Data Bank1MUJ
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Cryo-EM structure of the rhodopsin-Gαi-βγ complex reveals binding of the rhodopsin C-terminal tail to the Gβ subunit\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Nikolaus Grigorieff as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Dan Oprian (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The authors describe the cryo-EM structure of a rhodopsin-Gαi-βγ complex, bound to a Fab fragment to aid structure determination. The structure reveals several important aspects of GPCR-G protein interactions. The described interactions between the C-terminal helix of Gαi (H5) with a network of residues on TMs 3, 5, 6 and 7/H8 is consistent with previous GPCR-G protein complexes and true for all receptor and G protein isoform. The interaction of ICL2 with αN/β1 of Gαi is also consistent with previous receptor-G protein complexes. The present structure offers insight into the diversity of the GPCR-G protein interactions since it provides a direct comparison of rhodopsin-Gi and rhodopsin-Gt complexes. The authors give a nice summary and analysis of the GPCR-G protein interfaces, comparing and contrasting recently reported cryo-EM structures of the GPCR-G protein complexes. What distinguishes this structure from previous complexes is an apparent interaction of the rhodopsin C-terminus with Gβ. This \"C-tail\", previously reported as unstructured in either the inactive rhodopsin structure or in complex with G proteins, appears to migrate away from the putative membrane toward Gαi-Gβ interface.

Overall, the structure provides insight into the diversity of the GPCR-G protein interactions and highlights a novel interaction between the rhodopsin C-tail and the heterotrimer. It will serve as a guide to future work, which will no doubt be undertaken by multiple groups.

Essential revisions:

The following main concerns should be addressed by the authors:

1\) The rhodopsin C-tail interaction with the G protein is one of the main discoveries of this work. The manuscript would be strengthened if the authors could discuss in more depth the role of the residues involved in this interaction, particularly on the G protein (both subunits). Are they important for G protein recruitment and activation? Is there evidence, other than the new structure presented here, to validate the model?

2\) Details of the final density map shown in Figure 1---figure supplements 6, and 7 and Figure 3---figure supplement 3 suggest that map features are weak or ambiguous in some places. Especially density for the C-tail and intracellular loop 2 appears to be weak. Since the main conclusions of the work are based on these regions, the authors should describe in more detail how they built the model in these regions and how they characterized potential errors.

3\) Helix 8 of rhodopsin in the Gi complex is only composed of two turns whereas in all other rhodopsin structures (inactive Rho, metaRho, opsin, Rho-Gt, and Rho-arrestin) it appears to have three turns. A 3-turn helix may be expected when it is capped by palmitoylation at C322/C323. Is the 2-turn helix observed by the authors the result of depalmitoylation? Allowing the C-terminus to unravel by one turn may allow it to extent into the Gα-Gβ interface. Perhaps one of the reasons why a C-tail interaction with the G protein has not been observed in other rhodopsin complexes is the palmitoylation of the cysteines. Previous studies have suggested that depalmitoylated rhodopsin display normal G protein coupling but the receptor is quite unstable and can result in various retinopathies. Is it possible that the partial unraveling of the helix 8, and the resulting novel interactions, are the result of depalmitoylation? What can the authors say about the palmitoylation state of rhodopsin in their complex?

4\) Is it possible that the structure of helix 8 is affected by the detergent used to reconstitute the complex? In a membrane, the 3-turn helix 8 may be stabilized owing to its amphipathicity. This should be discussed by the authors.

Reviewer \#1:

The authors describe the cryo-EM structure of a rhodopsin-Gαi-βγ complex, bound to a Fab fragment to aid in image processing. They built a model into the map, including the C-terminal tail of rhodopsin, which appears to interact with the Gβ subunit. The C-tail has not been observed in previous rhodopsin-G protein structures and the authors suggest that the interactions they observe are important for specific binding of G proteins to the receptor. Comparing their structure with other GPCR structures, the authors show that certain amino acid residues make conserved contacts between the receptor and G proteins that are subtype specific.

Mapping the specific contacts between the receptor and the G protein heterotrimer is important for understanding the molecular mechanism of GPCR signaling pathways, and the present work represents, therefore, an important advance in the field. However, details of the final density map shown in Figure 1---figure supplements 6 and 7 and Figure 3---figure supplement 3 suggest that map features are weak or ambiguous in some places. Especially density for the C-tail and intracellular loop 2 appears to be weak. Since the main conclusions of the work are based on these regions, the authors should describe in more detail how they built the model in these regions and how they characterized potential errors.

Reviewer \#2:

The CryoEM structure of a complex between rhodopsin and heterotrimeric Gai•Gbg reveals several important aspects of GPCR-G protein interactions. Among these, interactions between the C-terminal helix of Gαi (α5, or H5) with a network of residues on TMs 3, 5, 6 and 7/H8 is consistent with previous GPCR-G protein complexes, regardless of the receptor or G protein isoform. The interaction of ICL2 with the αN-β1 of Gαi is also consistent with previous receptor-G protein complexes. The structure does provide insight into the diversity of the GPCR-G protein interactions since it provides a direct comparison of Rho-Gi and Rho-Gt complexes. The authors provide a nice summary and analysis of the GPCR-G protein interfaces comparing and contrasting recently reported cryoEM structures of the GPCR-G protein complexes. What distinguishes this structure from previous complexes is an apparent interaction of the rhodopsin C-term with Gβ. In this current structure the C-terminal domain, previously reported as unstructured in either the inactive rhodopsin structure or in complex with G proteins, appears to migrate away from the putative membrane toward Gαi-Gβ interface.

Overall, the structure does provide some additional insight into the diversity of the GPCR-G protein interactions and highlights a possible novel interaction with the Rho C-term and the heterotrimer. However, there is really a lack of experimental data to both validate the structural model and also to provide some functional relevance of this potentially interesting interaction.

Rho C-term-G protein interaction: The Rho C-terminal interaction with the G protein would represent a novel interaction. It is surprising that the authors did not devote more attention in the manuscript to highlighting and characterizing the precise role of the residues involved in the interaction, particularly on the G protein (both subunits). Moreover, like any other structure, the model needs to be tested in some functional assay. Some attempt to validate the structure and the C-terminal interaction with the G protein heterotrimer should be made, at least to determine its physiological or pathological relevance. Site-directed mutagenesis of candidate interacting residues and examining their role in G protein recruitment and activation would be logical studies.

From the models provided it appears that Helix 8 of rhodopsin in the Gi complex is only composed of two turns whereas Helix 8 in all other rho structures (inactive Rho, metaRho, opsin, Rho-Gt, and Rho-arrestin) appear to have a three-turn helix. One of the reasons a 3-turn helix is logical is that helix 8 of Rho is capped by palmitoylation at C322/C323. This would suggest that perhaps the Rho isolated in the complex described in this current study is depalmitoylated. Allowing the C-term to unravel by one turn may allow the C-term to extent into the Gα-Gβ interface. Perhaps one of the reasons why such interactions with other Rho-G protein structures have not been observed is that their palmitoylated cysteines may be intact. Previous studies have suggested that depalmitoylated Rho appears to display normal G protein coupling but the receptor is quite unstable and can result in various retinopathies. In this current study it would suggest that unraveling of the helix 8, as a result of depalmitoylation may allow for unique rho-G protein interactions. If this is the case then the palmitoylation state of rho should be tested.

A complicating factor is that helix 8 may be influenced by the detergent environment used in the sample preparation and EM imaging. In a membrane environment the entire 3-turn helix 8 may be stabilized owing to its amphipathicity. In detergent micelles, and particularly if helix 8 is depalmitoylated, it is likely that the influence of amphipathicity may be negated and thus allow helix unraveling.

Reviewer \#3:

The manuscript by Tsai et al. entitled \"Cryo-EM structure of the rhodopsin-Gαi-βγ complex reveals binding of the rhodopsin C-terminal tail to the Gβ subunit\" is a well-written description of a study in which the authors determine the three-dimensional structure of a rhodopsin-G protein complex to a nominal global resolution of 4.38 Å using cryo-electron microscopy. The major new insight from this study is the observation of density extending from H8 of the receptor into the Gβ subunit of the heterotrimeric G protein, a feature not observed in previous structures and one which the authors use to rationalize interactions of the receptor with not only the G protein but also other signaling partners such as the receptor kinases. The experiments are well designed, the results are clear-cut, and the conclusions rest soundly on the results. The study is timely and will appeal to a broad readership.

10.7554/eLife.46041.040

Author response

> Essential revisions:
>
> The following main concerns should be addressed by the authors:
>
> 1\) The rhodopsin C-tail interaction with the G protein is one of the main discoveries of this work. The manuscript would be strengthened if the authors could discuss in more depth the role of the residues involved in this interaction, particularly on the G protein (both subunits). Are they important for G protein recruitment and activation? Is there evidence, other than the new structure presented here, to validate the model?

We thank the reviewers for pointing out this oversight from our side, as we indeed did not discuss the residues in the Gα and Gβγ subunits involved in the interaction with the receptor C-tail. The revised text now includes a more detailed discussion of these residues, including a new panel D in Figure 2 depicting these interactions, and new supplementary figures showing the electrostatic potentials on the receptor/Gα/Gβ interface (Figure 2---figure supplement 1) and the sequence conservation of the interacting residues in Gα and Gβγ (Figure 2---figure supplement 2).

"In our G protein complex, the C-tail stretches over a polar surface on the cleft between Gα and Gβ, interacting with both subunits (Figure 2C and D). \[...\] Interestingly, these regions in Gα and Gβ that contact the receptor C-tail are also involved in recognition of GRK2 (Tesmer, et al., 2005)."

A recently published cryo-EM structure of the M1 muscarinic acetylcholine receptor in complex with G11 (Maeda et al., 2019) also reveals the proximal part of the receptor C-tail (11 residues), which binds the G protein in essentially the same conformation as in our structure. This information has also been included in the revised text.

"The EM map reveals a density on the Gβ subunit as continuation of H8 of the receptor (Figure 2A), which corresponds to the C-tail of rhodopsin. This feature has only been observed in the recent structure of the M1 muscarinic acetylcholine receptor in complex with G11 (Maeda et al., 2019)."

> 2\) Details of the final density map shown in Figure 1---figure supplements 6, and 7 and Figure 3---figure supplement 3 suggest that map features are weak or ambiguous in some places. Especially density for the C-tail and intracellular loop 2 appears to be weak. Since the main conclusions of the work are based on these regions, the authors should describe in more detail how they built the model in these regions and how they characterized potential errors.

In the 'Materials and methods' section of the revised manuscript, we describe in more detail the modeling process of the rhodopsin C-tail.

"After initial refinement using the phenix.real_space_refine in the Phenix suite (Adams et al., 2010), the C-tail of rhodopsin was modeled by manually building the residues 324-335 in the unassigned density near H8 and Gβ as a continuation of H8 using Coot (Emsley and Cowtan, 2004). \[...\] We observed that the modeled C-tail remains stable during the simulation (Figure 2---figure supplement 3), supporting a good agreement between the built atomic structure and the density map."

> 3\) Helix 8 of rhodopsin in the Gi complex is only composed of two turns whereas in all other rhodopsin structures (inactive Rho, metaRho, opsin, Rho-Gt, and Rho-arrestin) it appears to have three turns. A 3-turn helix may be expected when it is capped by palmitoylation at C322/C323. Is the 2-turn helix observed by the authors the result of depalmitoylation? Allowing the C-terminus to unravel by one turn may allow it to extent into the Gα-Gβ interface. Perhaps one of the reasons why a C-tail interaction with the G protein has not been observed in other rhodopsin complexes is the palmitoylation of the cysteines. Previous studies have suggested that depalmitoylated rhodopsin display normal G protein coupling but the receptor is quite unstable and can result in various retinopathies. Is it possible that the partial unraveling of the helix 8, and the resulting novel interactions, are the result of depalmitoylation? What can the authors say about the palmitoylation state of rhodopsin in their complex?

Regarding the structure of helix 8, while we observe density up to residue L321(8.58) (Figure 1---figure supplement 6A), the density weakens around residues C322 and C323. However, we do not expect that rhodopsin is depalmitoylated, as our construct was expressed and handled in conditions that have been shown to retain all post-translational modifications (Standfuss et al., 2011; Deupi et al., 2012; Singhal. et al., EMBO Rep. 2013, 14, 520--526; Singhal et al., EMBO Rep. 2016, e201642671--10). While there is indeed local flexibility or structural heterogeneity at the palmitoylation site, possibly due to an impaired interaction of the palmitoyl with the detergent micelle (Glukhova et al., 2018), we expect that helix 8 retains an overall structure that resembles the 3-turn helix observed in all rhodopsin structures. Such 3-turn helix 8 allowed us to build the C-tail into the neighboring density, and MDFF simulations (see above) show that this arrangement is stable and that the interaction with the G protein does not require partial unraveling of helix 8, at least in the context of the present structure.

Part of this information is now included in the 'Materials and methods' section of the revised manuscript.

"The N2C/M257Y/D282C mutant of bovine rhodopsin was expressed as described (Deupi et al., 2012) in human embryonic kidney (HEK) 293 GnTI− cells, which retain all post-translational modifications of the native protein including palmitoylation of Cys residues at positions 322 and 323 (Standfuss et al., 2011). Cell lines were tested and confirmed to be mycoplasma-free."

> 4\) Is it possible that the structure of helix 8 is affected by the detergent used to reconstitute the complex? In a membrane, the 3-turn helix 8 may be stabilized owing to its amphipathicity. This should be discussed by the authors.

In this work we used the detergent lauryl maltose-neopentyl glycol (LMNG), which is a common choice in structural determination of GPCR-G protein complexes by cryo-EM (Munk et al., 2019). Among these, helix 8 in the μ-opioid receptor (Koehl et al., 2018) is not well resolved, while its density is clear in the adenosine A1 receptor (Draper-Joyce et al., 2018), in the M1 and M2 muscarinic acetylcholine receptors (Maeda et al., 2019), and, most notably, in the class B calcitonin (Liang et al., Nature 2017, 546, 118--123) and GLP-1 (Liang et al., Nature 2018, 555, 121--125) receptors. Thus, the use of LMNG as a detergent to reconstitute the complex does not seem to be a major factor in the overall structure of helix 8. However, there exists the possibility that the detergent micelle affects locally the structure of helix 8. Indeed, we observe poor density around residues C322 and C323, at the transition to the C-terminus. This is also the more flexible region in our MDFF simulation (Figure 2---figure supplement 3). This local flexibility or structural heterogeneity may arise from impaired interactions of the receptor with the detergent micelle (Glukhova et al., 2018).

We have added this information in the legend of Figure 2A of the revised manuscript, which depicts the poor density around residues C322 and C323.

"Figure 2. The C-terminal tail of rhodopsin. (A) The EM map is contoured at two different levels to show the continuity of the density. \[...\] TM7, H8 and the C-tail of the receptor are colored in blue, Gα in green, Gβ in yellow, and Gγ in magenta."

> Reviewer \#1:
>
> \[...\] Mapping the specific contacts between the receptor and the G protein heterotrimer is important for understanding the molecular mechanism of GPCR signaling pathways, and the present work represents, therefore, an important advance in the field. However, details of the final density map shown in Figure 1---figure supplements 6 and 7 and Figure 3---figure supplement 3 suggest that map features are weak or ambiguous in some places. Especially density for the C-tail and intracellular loop 2 appears to be weak. Since the main conclusions of the work are based on these regions, the authors should describe in more detail how they built the model in these regions and how they characterized potential errors.

We thank the reviewer for his praise. His concerns are addressed in point 2 of the "Essential revisions" section above.

> Reviewer \#2:
>
> \[...\] Overall, the structure does provide some additional insight into the diversity of the GPCR-G protein interactions and highlights a possible novel interaction with the Rho C-term and the heterotrimer. However, there is really a lack of experimental data to both validate the structural model and also to provide some functional relevance of this potentially interesting interaction.
>
> Rho C-term-G protein interaction: The Rho C-terminal interaction with the G protein would represent a novel interaction. It is surprising that the authors did not devote more attention in the manuscript to highlighting and characterizing the precise role of the residues involved in the interaction, particularly on the G protein (both subunits).

We thank the reviewer for pointing out this glaring omission in our study. We address this concern in point 1 of the "Essential revisions" section above.

> Moreover, like any other structure, the model needs to be tested in some functional assay. Some attempt to validate the structure and the C-terminal interaction with the G protein heterotrimer should be made, at least to determine its physiological or pathological relevance. Site-directed mutagenesis of candidate interacting residues and examining their role in G protein recruitment and activation would be logical studies.

We thank the reviewer for this positive criticism. We believe that this is a structural study, and that the determination of the pathological relevance of the proposed interaction between the C-terminus of the receptor and the G protein is beyond the scope of our work. However, we agree that further validation and characterization of this interaction is required. We are currently using NMR to assess the binding of the rhodopsin C-terminus to the entire heterotrimeric Gi protein complex. This, and additional biophysical and biochemical characterization, will be part of further studies.

Interestingly, the recent publication of the cryo-EM structure of the M1 muscarinic acetylcholine receptor in complex with G11 (Maeda et al., 2019) supports our structure of the C-tail (see point 1 of the "Essential revisions" section above).

> From the models provided it appears that Helix 8 of rhodopsin in the Gi complex is only composed of two turns whereas Helix 8 in all other rho structures (inactive Rho, metaRho, opsin, Rho-Gt, and Rho-arrestin) appear to have a three-turn helix. One of the reasons a 3-turn helix is logical is that helix 8 of Rho is capped by palmitoylation at C322/C323. This would suggest that perhaps the Rho isolated in the complex described in this current study is depalmitoylated. Allowing the C-term to unravel by one turn may allow the C-term to extent into the Gα-Gβ interface. Perhaps one of the reasons why such interactions with other Rho-G protein structures have not been observed is that their palmitoylated cysteines may be intact. Previous studies have suggested that depalmitoylated Rho appears to display normal G protein coupling but the receptor is quite unstable and can result in various retinopathies. In this current study it would suggest that unraveling of the helix 8, as a result of depalmitoylation may allow for unique rho-G protein interactions. If this is the case then the palmitoylation state of rho should be tested.

This concerns is addressed in point 3 of the "Essential revisions" section above.

> A complicating factor is that helix 8 may be influenced by the detergent environment used in the sample preparation and EM imaging. In a membrane environment the entire 3-turn helix 8 may be stabilized owing to its amphipathicity. In detergent micelles, and particularly if helix 8 is depalmitoylated, it is likely that the influence of amphipathicity may be negated and thus allow helix unraveling.

This concerns are addressed in point 4 of the "Essential revisions" section above.

> Reviewer \#3:
>
> The manuscript by Tsai et al. entitled \"Cryo-EM structure of the rhodopsin-Gαi-βγ complex reveals binding of the rhodopsin C-terminal tail to the Gβ subunit\" is a well-written description of a study in which the authors determine the three-dimensional structure of a rhodopsin-G protein complex to a nominal global resolution of 4.38 Å using cryo-electron microscopy. The major new insight from this study is the observation of density extending from H8 of the receptor into the Gβ subunit of the heterotrimeric G protein, a feature not observed in previous structures and one which the authors use to rationalize interactions of the receptor with not only the G protein but also other signaling partners such as the receptor kinases. The experiments are well designed, the results are clear-cut, and the conclusions rest soundly on the results. The study is timely and will appeal to a broad readership.

We wholeheartedly thank the reviewer for his compliments. His comments have been incorporated into the revised manuscript.
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